Rohit Katial
National Jewish Health · 26 works · 36 citations · h-index 2
Top works
- Abstracts
- Asthma exacerbation rate reduction with benralizumab in an integrated analysis of the real-world XALOC-1 study
- Towards Clinical Remission in Severe Asthma: An Analysis of Patients Treated with Benralizumab in the Phase 3b ANDHI Trial
- Clinical symptoms, comorbidities, treatment patterns and time to diagnosis in patients with eosinophilic oesophagitis in England: a retrospective cohort study
- Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice
- Clinical Characteristics of Patients with Eosinophilic Esophagitis in the UK: A Retrospective Analysis of the Clinical Practice Research Datalink (CPRD) Database
- Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: A post hoc analysis
- PATIENT-REPORTED SYMPTOMS OF EOSINOPHILIC ESOPHAGITIS IN THE UNITED STATES: EVIDENCE FROM REAL-WORLD CLINICAL PRACTICE
- CHARACTERIZATION OF PATIENTS WITH EOSINOPHILIC ESOPHAGITIS MANAGED BY GASTROENTEROLOGISTS AND ALLERGISTS: REAL-WORLD CLINICAL PRACTICE EVIDENCE
- S505 Characteristics of and Healthcare Cost Drivers Among U.S. Patients With Eosinophilic Esophagitis With High versus Non-High All-Cause Costs: An Analysis of Insurance Claims Data
- Dupilumab With Medium-Dose Inhaled Corticosteroids Versus Omalizumab With High-Dose Inhaled Corticosteroids Improves Clinical Outcomes In Patients With Coexisting Chronic Rhinosinusitis With Nasal Polyps And Uncontrolled Asthma
- TWICE-YEARLY DEPEMOKIMAB IMPROVES PEAK EXPIRATORY FLOW AND RESCUE INHALER USE IN PATIENTS WITH ASTHMA: SWIFT-1/2
- High systemic corticosteroids burden among patients with moderate-to-severe asthma in the United States
- B32-11 Efficacy of Dupilumab With Medium Inhaled Corticosteroid Dose Versus Omalizumab With High Inhaled Corticosteroid Dose in Patients With Coexisting Chronic Rhinosinusitis With Nasal Polyps and Uncontrolled Asthma: Post Hoc Analysis of Everest
- B32-26 Long-term Efficacy of Dupilumab in Patients With Asthma and Ongoing Coexisting Type 2 Inflammatory Conditions
- Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
- B32-19 Long-Term Outcomes in Traverse in Patients With Type 2 Asthma Treated With Dupilumab Based on Clinical Remission Status at the End of Quest
- Escalation To High-Dose ICS Versus Dupilumab Initiation in Uncontrolled Asthma Patients on Medium-Dose ICS: A Matched Analysis of Administrative Claims
- Real-World Outcomes Following Asthma Treatment Escalation From Medium-Dose ICS to high-Dose ICS or Biologics
- Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study